UK shares: Scancell Holdings and Morses Club soar on fresh news!

These UK shares have shot higher today following the release of new market updates. Here’s what investors like me need to know.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

These two UK shares are soaring in Tuesday business. And here’s why.

The Scancell Holdings (LSE: SCLP) share price has risen strongly after it announced plans to run clinical trials for its COVIDITY vaccine programme. The UK medical share was recently 6% higher from Monday’s close, taking gains over the past 12 months to 303%.

Scancell said it intends to run Phase 1 trials for its novel Covid-19 vaccine during the second half. This follows the release of preclinical data on two of its lead bivalent vaccine candidates: SN15 (also known as SCOV1), and SN17 (known as SCOV2).

The COVIDITY programme is based on the UK healthcare share’s ImmunoBody DNA vaccine platform. It’s hoped its vaccine candidates will offer improved protection against new coronavirus variants of concern. This is “due to the inclusion of the highly conserved nucleocapsid N antigen in addition to the more variable spike (S) protein,” Scancell said.

Coronavirus 2019-nCoV Blood Samples Medical Concept

Trials ready to begin

A regulatory application to begin Phase 1 trials on unvaccinated individuals has been submitted to the South African Health Products Regulatory Authority (SAHPRA). A study isn’t possible in the UK because of the rapid rollout of Covid-19 vaccines here.

Scancell plans to gain approval from the Medicines & Healthcare products Regulatory Agency (MHRA) in the UK should Part 1 of the South African study demonstrate safety. Phase 1 trials here will see the SCOV2 vaccine given to recipients of two doses of an approved vaccine. The South African trials will be used to assess both SCOV1 and SCOV2.

Scancell chief executive Dr Cliff Holloway said: “There is a significant threat from future mutations of the SARS-CoV-2 virus, as we have seen with the rapid transmission of the Delta variant. Our next generation Covid-19 vaccine has the potential to work alongside currently approved vaccines by protecting the population against new variants of SARS-CoV-2.”

Another soaring UK share

The Morses Club (LSE: MCL) share price has also ballooned on Tuesday following the release of fresh trading numbers. It’s currently 8% higher on the day, and up 72% over the past 12 months.

Morses Club said it’s enjoyed “a steady increase in customer demand across all lending products in both its Home Collected Credit and digital divisions.

Customer numbers at its digital arm ballooned 40% between March and May. And total loan book balances increased 99% versus the end of February. Meanwhile, new credit issued came in 33% above expectations, and collections performance was ahead of budget.

Elsewhere, customer numbers at its Home Collected Credit unit clocked in at 144,000 as of May. This was 7,000 fewer than the UK financial share reported three months earlier. However, collections at the division are more than double the number Morses Club had expected. And total new credit issued was also 16% ahead of company expectations.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »